NEWS
Latest News
Check out our latest news hits and coverage on AXIM’s latest innovations.
Partner News: Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform
Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform Business Wire TAMPA, Fla. -- July 25, 2023 Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value...
Optometric Management: Perform a Pre-Fit Ocular Surface Evaluation
The Rapid Quantitative Tear Test for MMP-9 from AXIM Biotechnologies Inc. was featured in a list of DED Diagnostic tools in Optometric Management.com. See the list below: DED Diagnostic Items* BLINK ASSESSMENT iPEDA Blink Analyzer MEIBOMIAN GLAND EXPRESSION Flexx MG...
Benzinga: Will This Dry Eye Rapid Test Prove To Be A Rapid Success?
The biotech firm AXIM Biotechnologies Inc. AXIM reports that it has developed fast, point-of-care tests to help eye doctors detect dry eye syndrome, a big issue in today’s world. It is important to differentiate from simple allergies for proper care and treatment. Up...
AXIM Biotech develops rapid quantitative tear test for MMP-9, an inflammatory biomarker for DED
The challenge has been in early detection of inflammation. Matrix metalloproteinase-9 (MMP-9), an inflammatory biomarker consistently elevated in the tears of dry eye patients, may accelerate early diagnosis when detected. AXIM Biotechnologies, Inc. recently announced...
Axim develops rapid test for dry eye inflammatory biomarker
Axim Biotechnologies has developed a rapid quantitative tear test to detect an inflammatory biomarker for dry eye disease, according to a press release. Diagnosis and treatment of dry eye disease (DED) can be difficult because of the discordance between signs and...
AXIM’ Partner Empowered Files EUA With FDA For Use Of Rapid COVID-19 Neutralizing Antibody Test
AXIM Biotechnologies Inc. (AXIM.OB) said that its manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization or EUA application with the US Food and Drug Administration for the approval to use ImmunoPass, the company's rapid test that...
What is a COVID-19 “Immunity Passport” and Why is it Better Than a “Vaccine Passport”?
After a little over a year of expedited research, financial hardship and over 500K deaths in the US, we're finally starting to see the light at the end of the COVID-19 tunnel. But while the widespread rollout of vaccines has been encouraging, there are many additional...
What’s a Vaccine Passport and Do You Need One?
Would an “immunity passport” be more effective? The vaccines are still in the early stages of being studied, but they’re thought to be highly effective. However, there are questions that remain. For example, it’s not clear if a vaccinated person who gets the virus can...
AXIM Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test
The Company conducted two studies, one in partnership with the Company’s manufacturing partner Empowered Diagnostics and the second in partnership with a top accredited university medical center. The main goal of these studies was to identify the ability of operators...
Beating the Covid-19 crisis: the role of vaccine boosters
Vaccine boosters could have a dual positive impact on the Covid-19 pandemic. They can boost the immune response against the original SARS-CoV-2 virus, as well as provide methods to overcome the emerging viral variants that could render existing vaccines ineffective....
AXIM completes point-of-care trials for ImmunoPass COVID-19 test
AXIM Biotechnologies (OTCQB:AXIM) has completed point-of-care clinical trials on its ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies. The test aims to help understand COVID-19 immunity, validate vaccine’s...
Neutralizing antibodies and COVID-19 vaccines
The CDC estimates that in the past 20 years, vaccines have saved more that 21 million lives. There are many different types of vaccines that provide protection against infectious diseases. Some examples of diseases for which vaccines elicit protective immunity include...
AXIM Biotechnologies, Inc. – COVID-19 Research
John Huemoeller, CEO of AXIM Biotechnologies, an international healthcare solutions company based in San Diego targeting oncological and COVID-19 research, discusses three first-of-their-kind COVID-19 neutralizing antibody tests. They have developed the world’s first...
AXIM Biotechnologies begins trials on Immunopass rapid diagnostic test
AXIM Biotechnologies (OTCQB:AXIM) announces the start of clinical trials for ImmunoPass, the company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. Measuring neutralizing antibodies in people after...
Tests for the test makers
IPM spoke with AXIM Biotech CEO John Huemoeller to see how his firm are going about seeking patent protection for its Covid-19 tests. Obtaining IP rights protections for Covid-19 related treatments and tests is the number one public health priority right now.The race...
FDA authorizes lateral flow antigen test as first OTC fully at-home test for COVID-19
In what U.S. FDA commissioner Stephen Hahn billed as “a major milestone” in testing for the COVID-19 pandemic, the FDA has granted an emergency use authorization (EUA) to Ellume Ltd., of East Brisbane, Australia, for the company’s COVID-19 home test. The rapid...
AXIM files amended EUA for diagnostic test for COVID-19 neutralizing antibodies
AXIM Biotechnologies (OTCQB:AXIM -2.4%) has filed an amended Emergency Use Authorization (EUA) application with the FDA. AXIM first filed the EUA in September for measuring COVID-19 neutralizing antibodies in plasma and serum through its rapid diagnostic test. The...
New ELISA-Based COVID-19 Test Detects and Ranks SARS-CoV-2 Neutralizing Antibodies by Their Potency
A new enzyme-linked immunosorbent assay (ELISA)-based COVID-19 diagnostic test detects and ranks SARS-CoV-2 neutralizing antibodies by their potency in a simple and relatively short test time. The test developed internally by AXIM Biotechnologies, Inc. (San Diego, CA,...
Coronavirus company news summary – AXIM develops ELISA-based neutralising antibody diagnostic test for Covid-19 – ixlayer and CIC Health partner to expand Covid testing in US schools and universities
Intrivo Diagnostics announced that it has entered into a national distribution agreement with Concordance Healthcare Solutions and NDC to start the distribution and commercialisation of New Jersey-based Access Bio’s CareStart™ line of coronavirus testing products...
BioWorld Others News Note for Dec 3
3M, of St Paul, Minn., said it is planning to initiate restructuring actions that will impact all business groups, functions and geographies. The restructuring is expected to affect about 2,900 positions globally. Santa Clara, Calif.-based Agilent Technologies...
A face mask coated in a biological mousetrap for the virus? Just one of AXIM’s inventions.
SAN DIEGO (KGTV) — A small San Diego biotech is trying to give face masks an added layer of defense by spraying the liner with a biological bait designed to be a mousetrap for the coronavirus. AXIM Biotechnologies is also developing a next-generation rapid antibody...
Making a better facemask, Axim Biotech looks to be a leader protecting people from COVID-19
Axim Biotech (OTCQB: AXIM) CEO John Huemoeller joined Steve Darling from Proactive with news the company is working on a number of initiatives around protecting people from COVID-19. One of those is a much better facemask and Huemoeller explains how. Huemoeller also...
World’s First Face Mask Designed to Capture and Deactivate SARS-CoV-2 Could Lower COVID-19 Infection Rate
By HospiMedica International staff writers Posted on 30 Sep 2020 The outbreak of respiratory infection based pandemic diseases like COVID-19 is fueling global demand for face masks among frontline health workers such as first responders, nurses, and medical...
Coronavirus company news summary – Color receives EUA for Covid-19 self-collection kit – Vivera Pharmaceuticals launches BIOZONE device
AXIM Biotechnologies has filed an Emergency Use Authorisation (EUA) application with the US Food and Drug Administration (FDA) for its first-in-class rapid diagnostic test for Covid-19. AXIM’s rapid diagnostic test is expected to be the market’s first Covid-19 rapid...
AXIM Biotechnologies files EUA with FDA for Covid-19 rapid diagnostic test for neutralising antibodies
AXIM’s rapid diagnostic test is expected to be the market’s first Covid-19 rapid diagnostic test for measuring levels of functional neutralising antibodies in a lateral flow assay format. AXIM Biotechnologies, an international healthcare solutions company targeting...
First-in-Class Rapid Diagnostic Test Measures COVID-19 Neutralizing Antibodies in Plasma and Serum
By HospiMedica International staff writers Posted on 17 Sep 2020 A new rapid diagnostic test is expected to be the market’s first COVID-19 rapid diagnostic test for measuring the levels of functional SARS-CoV-2 neutralizing antibodies in a lateral flow assay format....
BioWorld News to Note for Sept 16 2020
San Diego-based Axim Biotechnologies Inc., an international health care solutions company targeting oncological and COVID-19 research, has filed an emergency use authorization (EUA) application with the U.S. FDA for measuring COVID-19 neutralizing antibodies in plasma...
Bulls Take Charge of Axim Biotechnologies Inc (OTCMKTS: AXIM)
By Microcap Daily Axim Biotechnologies Inc (OTCMKTS: AXIM) is making a big move to the upside after the Company announced strong results for its Rapid NeuCovix™ test which was compared to a gold standard pseudovirus-based test. NeuCovix™ accurately classified serum...
COVID Fighters Rewarded on Markets
By Baystreet The old adage, "he also serves who only sits and waits," is being severely tested these days with the impatience millions are feeling to see some sort of banishment of the deadly COVID-19. Thomas Edison’s statement “he also serves who hustles while he...
Coronavirus company news summary – BD receives additional orders for 177 million injection devices – AXIM develops Covid-19 test for neutralising antibodies
By Verdict Medical Devices Medical Marijuana has announced that its investment company AXIM Biotechnologies has developed a rapid diagnostic test that measures the levels of functional neutralising antibodies that are said to prevent SARS-CoV-2 (Covid-19) infection....
First-in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies Could Serve as Immunity Passport for Vaccine Developers
By LabMedica.com A new rapid diagnostic test for measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells could serve as an ‘Immunity Passport’ for vaccine developers around the world as they begin...
AXIM Biotechnologies unveils rapid test for neutralizing antibodies, files Pre-EUA with the FDA
By Medical Laboratory Observer AXIM Biotechnologies, an healthcare solutions company focused on oncological research, has announced the development of NeuCovix, a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent...
First-in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies Could Serve as Immunity Passport for Vaccine Developers
By HospiMedica International staff writers Posted on 16 Jul 2020 A new rapid diagnostic test for measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells could serve as an ‘Immunity Passport’ for...